jnk-2在肾癌中的表达与索拉非尼靶向治疗敏感性的研究

《jnk-2在肾癌中的表达与索拉非尼靶向治疗敏感性的研究》由会员上传分享，免费在线阅读，更多相关内容在学术论文-天天文库。

1、分类号R737.11第四军医大学UDC616.6TheFourthMilitaryMedicalUniversity密级公开硕士学位论文JNK-2在肾癌中的表达与索拉非尼靶向治疗敏感性的研究杨平培养类别非全日制学位类型学术学位一级学科(专业类)临床医学二级学科(专业)外科学（泌外）研究方向晚期肾癌靶向治疗指导教师袁建林教授（主任医师）培养单位西京医院泌尿外科二O一五年十月独创性声明秉承学校严谨的学风与优良的科学道德，本人声明所呈交的论文是我个人在导师指导下进行的研究工作及取得的研究成果。尽我所知，除了文中特别加以标注和致谢的地方外，论文中

2、不包含其他人已经发表或撰写过的研究成果，不包含本人或他人已申请学位或其他用途使用过的成果。与我一同工作的同志对本研究所做的任何贡献均已在论文中作了明确的说明并表示了致谢。申请学位论文与资料若有不实之处，本人承担一切相关责任。论文作者签名：日期：保护知识产权声明本人完全了解第四军医大学有关保护知识产权的规定，即：研究生在校攻读学位期间论文工作的知识产权单位为第四军医大学。本人保证毕业离校后，发表论文等使用本论文工作成果时第一署名单位仍然为第四军医大学。学校可以公布论文的全部或部分内容（含电子版，保密内容除外），可以采用影印，缩印或其他复制手

3、段保存论文；学校有权允许论文被查阅和借阅，并在校园网上提供论文内容的浏览和下载服务。同意学校将论文加入《中国优秀博硕士学位论文全文数据库》和编入《中国知识资源总库》等，并可浏览和下载，同时享受《中国优秀博硕士学位论文全文数据库出版章程》规定的相关权益。论文作者签名：导师签名：日期：第四军医大学硕士学位论文目录缩略语表······························································································1中文摘要··············

4、················································································3英文摘要······························································································5前言··························································································

5、····7文献回顾·····························································································101.MAPK信号通路···········································································101.1.ERK通路：·······································································

6、····111.2Ras·······················································································121.3应激活化MAPK通路································································132.JNK信号通路在癌症中的作用·························································183.索拉非尼在肾癌中的作用····

7、···························································20正文······························································································25第一部分JNK-2在肾透明细胞癌中的表达及其与索拉非尼靶向治疗疗效的关系·············································································

8、··········251材料：················································································